Activating BRAF kinase mutations serve as oncogenic drivers in over half of all melanomas, a feature that has been exploited in the development of new molecularly-targeted approaches to treat this disease. -driven melanoma, particularly as a strategy to overcome acquired resistance to selective BRAF inhibitors.
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Introduction
Cutaneous melanoma ranks among the most aggressive and treatment-resistant human malignancies (1) and, at a time when the overall incidence and mortality rates for many cancer types are showing encouraging declines (2), the worldwide incidence of melanoma continues to increase (3) . Mutational activation of the serine-threonine kinase BRAF, resulting in dysregulation of the RAF/MEK/ERK MAPK signaling cascade, is a feature of over half of all malignant melanomas (4, 5) . The vast majority of BRAF mutations (>90%) are point mutations encoding for a valine-to-glutamic acid substitution at codon 600 (BRAF V600E ) (6) . The high frequency of these genetic modifications underscores a critical role for BRAF mutation in melanoma oncogenesis (1), as well as providing an actionable target for molecular therapeutic approaches in this disease.
Indeed, these considerations have been strikingly validated by the recent FDA approval of the first highly selective BRAF V600E inhibitor, vemurafenib, for patients with metastatic melanoma (7) .
Despite this clinical success, however, durable responses to vemurafenib are rare and most patients invariably relapse with drug-resistant disease within 6-8 months (8) . Strategies to counteract intrinsic and/or acquired resistance in mutant BRAF-driven melanoma have not yet been established, and this remains an ongoing clinical challenge for these cancers.
As is the case for a large number of oncogenes, the conformational stability of mutant BRAF is reliant on the activity of heat shock protein 90 (Hsp90) (9) , a ubiquitously expressed molecular chaperone. Hsp90 is required for the maturation and function of numerous cellular client proteins (10) , including others that have also been implicated in the pathogenesis of melanoma, such as CRAF, IGF-IR and AKT (11) . Further, tumor cells can exploit the Hsp90 chaperone machinery as a biochemical buffer to protect mutated oncoproteins (such as BRAF V600E ) from targeted degradation, thereby facilitating aberrant cell survival and oncogene addiction (11, 12) .
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Western blotting
Following respective treatments, tumor cells were disrupted in lysis buffer (Cell Signaling Technology) on ice for 10 min. Lysates were clarified by centrifugation and equal amounts of proteins resolved by SDS-PAGE before transfer to nitrocellulose membranes (Invitrogen, Carlsbad CA). Membranes were blocked with StartingBlock T20 blocking buffer (Thermo Scientific, Cambridge MA) and immunoblotted with the indicated antibodies. Antibody-antigen complexes were visualized using an Odyssey system (LI-COR, Lincoln, NE). 5x/week). Tumor growth inhibition was determined as described previously (17) .
In vivo xenograft tumor models

Multiple drug effect analysis
For combinatorial analysis, A375 cells were seeded into the viability assay and combination treatments of ganetespib with vemurafenib or AZD6244 were performed at fixed, non-constant ratios. Drugs were added to cell cultures for 72 h and viability measured by alamarBlue assay (Invitrogen, Carlsbad, CA). The nature of the interactions were evaluated using the combination index (CI) method (18) and values generated using Median Effect analysis (Calcusyn Software; Biosoft, Cambridge, UK). 
In-Cell
Results
Loss of viability and oncogenic signaling by ganetespib in BRAF mutant melanoma cells
The cytotoxic activity of ganetespib ( Fig. 1) 1A ). When the antiproliferative activity of these compounds was compared to that of ganetespib in A375 cells, it was found that ganetespib was four-to thirteen-fold more potent than AZD6244 or vemurafenib (19 vs. 81 and 255 nM, respectively; Fig. 1D ). Caspase 3/7 activity was quantified in A375 cells following inhibitor treatment as a measure of apoptotic induction (Fig. 1E ).
The data showed that ganetespib, but not vemurafenib or AZD6244, caused a potent and dosedependent elevation of activity at the 24 hour time point ( Supplementary Fig. S2 ). As shown in Fig. 2A , weekly administration of a sub-optimal dose (onethird MTD) of ganetespib (50 mg/kg) and 5x/week BID dosing with vemurafenib (25 mg/kg) reduced tumor growth by 36% and 71%, respectively (T/C values of 64% and 29%). On this regimen, vemurafenib exposure induced some toxicity, as measured by >20% body weight loss (2/7 animals) and one death (1/7) in this cohort; thus this dose was determined to be the MTD for this agent. Consistent with the in vitro findings, concurrent administration of both drugs at the same dose levels resulted in enhanced antitumor activity, suppressing tumor growth by 92%. This represented a significant improvement in efficacy over single agent ganetespib alone (p=0.01).
Combination treatment also resulted in lower toxicity than vemurafenib alone (2/7 animals vs. 3/7 in the vemurafenib single agent arm) and mean body weights are shown in Supplementary Fig.   S3A . Thus, ganetespib and vemurafenib, when combined, displayed superior antitumor efficacy compared to monotherapy in A375 melanoma xenografts.
Dual blockade of Hsp90 and MEK was subsequently evaluated using ganetespib and AZD6244.
Isobologram analysis showed synergistic effects for combinations of the two compounds in A375 cells in vitro ( Supplementary Fig. S1B ), however only a modest improvement in antitumor efficacy over either agent alone was observed in A375 xenografts on an AZD6244 (3 mg/kg, 5x/week) plus ganetespib (50 mg/kg, 1x/week) dosing regimen (Fig. 2B) . In contrast, single agent administration of the potent allosteric MEK inhibitor TAK-733 (Fig. 1A) at 3 mg/kg caused greater than 90% tumor growth inhibition. Importantly, even at this efficacious dose, co-treatment with ganetespib resulted in 22% tumor regression (Fig. 2C) . Both combination treatments were well tolerated, with no toxicity or significant changes in body weight observed over the 3 weeks of dosing ( Supplementary Fig. S3B,C) . (Fig. 3A) . At the molecular level, ganetespib potently abrogated MAPK and AKT signaling in these cells sufficient to account for its pro-apoptotic activity, whereas the other two agents had no effects on downstream ERK or AKT activity (Fig. 3B ).
Ganetespib overcomes acquired vemurafenib resistance
The clinical experience with vemurafenib has also shown that the efficacy of long-term treatment for melanoma patients is hampered by the invariable development of acquired resistance to the drug. It was important, therefore, to determine whether BRAF V600E mutant melanoma cells with acquired resistance to vemurafenib remained sensitive to ganetespib. To explore this experimentally, we generated vemurafenib-resistant A375 cells (A375-VR) by continuous selective culture. The activities of ganetespib and vemurafenib were then compared using parental A375 and A375-VR cells (Fig. 3C ). As expected, vemurafenib treatment resulted in dose-dependent cytotoxicity in the parental line, but had no effect on A375-VR cells. In contrast, ganetespib retained full potency against both lines, irrespective of vemurafenib resistance status.
Indeed, A375-VR cells remained several fold more sensitive to ganetespib compared to that of the parental line to vemurafenib. Importantly, these effects were recapitulated in vivo, where 
ganetespib, but not vemurafenib, significantly inhibited tumor growth of A375-VR xenografts (Fig.   3D ).
Elevations in steady-state ERK signaling sensitize vemurafenib-resistant melanoma cells to MEK inhibition
Next we investigated the molecular profiles of the vemurafenib-resistant and sensitive cell lines, and their response to inhibitor treatment (Fig. 4A) . Compared to the parental line, A375-VR cells showed higher basal activation of ERK signaling, as well as increased MET receptor expression (Fig. 4A) . These oncogenic signaling cascades, in particular the enhanced ERK activity, were maintained in A375-VR cells even following BRAF inhibition. Notably, while ganetespib treatment effectively destabilized BRAF, CRAF, MET, and p-MEK proteins in A375-VR cells, p-ERK levels were reduced, but not completely abrogated, by the compound.
Having identified a potential role for sustained ERK signaling in the vemurafenib-resistant phenotype of A375-VR cells, we sought to identify relevant agents that could overcome this activity. We screened a library of 194 kinase inhibitors using an In-Cell Western assay, performed in the continuous presence of 5 μM vemurafenib, to quantify levels of p-ERK. Compounds that reduced levels of p-ERK by >50% are listed in Supplementary Table S1 . In agreement with the data presented in Fig. 4A , 18% of p-ERK levels remained following ganetespib treatment. As a class, MEK inhibitors showed the most consistent and potent activity, reducing ERK activity by 90%. These data suggested that MEK activity was essential for the elevated ERK phosphorylation status.
Based on these observations we selected a group of compounds for a dose-response analysis of ERK inactivation and cytotoxicity, including multi-kinase inhibitors and other drugs targeting upstream modulators that impinge on ERK activity (Table 2) viability at low nanomolar concentrations. As a control, we included the BRAF inhibitors PLX-4720 and GCD-0879, which had no effect on survival or p-ERK levels. In addition, despite the increased expression of MET in A375-VR cells, the dual MET/ALK inhibitor crizotinib did not deplete ERK activity beyond 50% and was only weakly cytotoxic (IC 50 , 1734 nM).
Inhibition of BRAF V600E enhances the activity of MEK inhibitors in vemurafenib-resistant melanoma cells
These findings are in concordance with recent reports that BRAF V600E melanoma cells become dependent on reactivation of ERK signaling despite ongoing inhibition of mutant BRAF (22, 23) .
We therefore evaluated the antiproliferative activity of TAK-733 in A375-VR cells in both the presence and absence of the BRAF inhibitor (Fig. 4B) . Consistent with the data in Table 2 , A375-VR cells were acutely sensitive to MEK inhibition in the presence of vemurafenib however, upon removal of the BRAF antagonist, a greater than log-shift decrease in sensitivity occurred. A similar response was observed for AZD6244 ( Supplementary Fig. S4 ). Thus continued suppression of BRAF V600E appears important for promoting sensitivity to targeted MEK inhibition after acquired resistance to vemurafenib has been established. These data are in agreement with other models showing that MAPK reactivation predicts for MEK inhibitor sensitivity in the resistance setting (6, 24) .
Notably, treatment with vemurafenib or TAK-733 alone did not effectively block ERK reactivation in A375-VR cells, although p-ERK levels were abrogated when the two inhibitors were combined (Fig. 4C) . Moreover, when TAK-733 was dosed with ganetespib, the addition of the MEK inhibitor was sufficient to overcome the activated ERK signal. Indeed this combination provided the most robust inhibition of MAPK and AKT signaling in A375-VR cells, with concomitant induction of apoptosis ( Fig. 4C) , highlighting a superior combinatorial benefit over vemurafenib plus TAK-733.
This finding was strikingly validated in vivo where TAK-733 displayed minimal single-agent efficacy in vemurafenib-resistant A375-VR xenografts, however the combination of ganetespib with TAK-733 induced tumor regression (38%) (Fig. 4D) In light of the exquisite dependence on oncogenic MAPK signaling for proliferation and survival, pharmacological inhibition of MEK has also emerged as an important strategy for therapeutic intervention in mutant BRAF-driven melanoma (27) . In accordance with preclinical predictions, the clinical evaluation of small molecule inhibitors of MEK has shown encouraging results, with superior response rates and outcomes compared to chemotherapy in this population (8, 28) .
However, response rates for MEK inhibitors are typically lower than those seen with selective BRAF inhibitors -thus the role of MEK inhibitor monotherapy in mutant BRAF melanoma, given the advent of approved BRAF-targeted agents, remains to be determined (8) . A number of combination trials investigating the dual blockade of mutant BRAF and MEK are currently underway, and early evidence suggests that this strategy may not only improve the efficacy over 
single agent treatments alone (29) , but may also be an effective approach to prevent or delay the onset of resistance due to ERK reactivation (30, 31) . Similar to what was found for vemurafenib, ganetespib was considerably more potent than AZD6244 in terms of MAPK pathway modulation and cytotoxic activity in BRAF V600E -driven melanoma cells. In vitro, strong synergistic activity was seen when ganetespib was used as a co-treatment with both vemurafenib and AZD6244 and these effects were more robustly recapitulated in vivo with the ganetespib + vemurafenib combination. Thus, our data strongly suggest that combining the modalities of 
survival (23) . Consistent with these reports, we observed elevated basal ERK activity in our model of acquired resistance generated by chronic exposure to vemurafenib (A375-VR). It is reasonable to suggest that the complexity of such resistance mechanisms to selective BRAF inhibitors may be overcome by the simultaneous targeting of multiple signaling nodes that is afforded by Hsp90 inhibition. In support of this, ganetespib retained full single-agent potency against vemurafenib-resistant cells and, indeed, they remained more sensitive to ganetespib compared to the parental line to vemurafenib.
Within the resistance setting, MAPK reactivation predicts for MEK inhibitor sensitivity (24) . As 
